Physician profile
Mohammad Anjum
NPI 1427086081
$2,988.91
in general payments reported to CMS, 2019-2025
19 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $355 · 2021: $202 · 2022: $125 · 2023: $353 · 2024: $430 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Travel and Lodging: $621 · Education: $81.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.12 |
| Travel and Lodging | $620.91 |
| Education | $81.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $853.16 | 2025 | Renal - Acute |
| Astrazeneca Pharmaceuticals LP | $445.10 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $299.97 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $199.45 | 2021-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $164.53 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $163.67 | 2021-2023 | Lupkynis |
| Amgen INC. | $159.56 | 2019-2023 | Parsabiv, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.84 | 2024 | Jardiance |
| Vifor Pharma, INC. | $94.80 | 2019-2023 | Veltassa, Korsuva |
| Ardelyx, INC. | $91.90 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $86.77 | 2019-2020 | |
| Lilly USA, LLC | $85.87 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $61.18 | 2019-2024 | Velphoro |
| Mallinckrodt Hospital Products INC. | $52.12 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $49.27 | 2024-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $40.57 | 2021-2024 | Rayaldee |
| Travere Therapeutics, INC. | $16.12 | 2023 | |
| Arbor Pharmaceuticals, INC. | $14.43 | 2019 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Anjum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.